Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy

American Journal of Nephrology

Volumn 40, Issue 2, 2014, Pages 157-163

  Konarzewski, Marcin ^a   Szolkiewicz, Marek ^b   Sucajtys Szulc, Elzbieta ^b   Blaszak, Joanna ^c   Lizakowski, Slawomir ^b   Swierczynski, Julian ^b   Rutkowski, Boleslaw ^b  

^a Wincent A Paulo Hospital in Gdynia   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c Department of Cardiology Pomeranian Cardiology Centers in Wejherowo   (Poland)

Author keywords

Hypercholesterolemia; PCSK 9; Renal failure

Indexed keywords

C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SERINE ENDOPEPTIDASES;

EID: 84906577482     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000365935     Document Type: Article

References (30)

1. Ferri N: Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. Scientifica 2012; 2012: 927352.
2. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK: The PCSK9 decade. J Lipid Res 2012; 53: 2515-2524.
3. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M: The secretory proprotein convertase neural apoptosis-regulated convertase 1(NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100: 928-933.
4. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomaldominant hypercholesterolemia. Nat Genet 2003; 34: 154-156.
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-1272.
6. Leren TP: Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004; 65: 419-422.
7. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, van Heyningen C, Soutar AK: Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005; 25: 2654-2660.
8. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116: 2995-3005.
9. Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W, Ehsani ME, Lu D, Konrad RJ, Eacho PI, Moller DE, Karathanasis SK, Cao G: Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007; 48: 1488-1498.
10. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R: Effect of a monoclonal antibody to PCSK9, REGN727/ SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012; 380: 29-36.
11. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59: 2344-2353.
12. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007; 48: 763-767.
13. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA: PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun 2008; 375: 69-73.
14. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH: Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009; 94: 2537-2543.
15. Verges B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B: Lack of association between plasma PCSK9 and LDLapoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis 2011; 219: 342-348.
16. Abujrad H, Mayne J, Ruzicka M, Cousins M, Raymond A, Cheesman J, Taljaard M, Sorisky A, Burns K, Ooi TC: Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis 2014; 233: 123-129.
17. Jin K, Park BS, Kim YW, Vaziri ND: Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: A cross-sectional study. Am J Kidney Dis 2014; 63: 584-589.
18. Heymann EP, Kassimatis TI, Goldsmith DJ: Dyslipidemia, statins, and CKD patients' outcomes-review of the evidence in the postsharp era. J Nephrol 2012; 25: 460-472.
19. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C: Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008; 374: 341-344.
20. Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE, Brown MS: Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311: 1658-1664.
21. Chmielewski M, Sucajtys-Szulc E, Kossowska E , Swierczynski J, Rutkowski B, Boguslawski W: Increased gene expression of liver SREBP-2 in experimental chronic renal failure. Atherosclerosis 2007; 191: 326-332.
22. Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G: Secreted proprotein convertase subtilisin/ kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun 2008; 370: 634-640.
23. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A: Oxidative stress and inflammation: implications in uremia and hemodialysis. Clin Biochem 2011; 44: 1189-1198.
24. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ: Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008; 49: 394-398.
25. Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chretien M: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008; 7: 22.
26. Wooten CJ, Adcock AF, Agina-Obu DI, Lopez D: Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor. Arch Biochem Biophys 2014; 545: 124-132.
27. Bilheimer DW, Stone NJ, Grundy SM: Metabolic studies in familial hypercholesterolemia: evidence for a gene-dosage effect in vivo. J Clin Invest 1979; 64: 524-533.
28. Wierzbicki AS, Viljoen A, Hardman TC, Mikhailidis DP: New therapies to reduce lowdensity lipoprotein cholesterol. Curr Opin Cardiol 2013; 28: 452-457.
29. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG: The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006; 281: 30561-30572.
30. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010; 51: 2714-2721.